CA3041033A1 - Monocyclic compounds useful as gpr120 modulators - Google Patents
Monocyclic compounds useful as gpr120 modulators Download PDFInfo
- Publication number
- CA3041033A1 CA3041033A1 CA3041033A CA3041033A CA3041033A1 CA 3041033 A1 CA3041033 A1 CA 3041033A1 CA 3041033 A CA3041033 A CA 3041033A CA 3041033 A CA3041033 A CA 3041033A CA 3041033 A1 CA3041033 A1 CA 3041033A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- mammal
- optionally substituted
- lcms
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393616P | 2016-09-12 | 2016-09-12 | |
| US62/393,616 | 2016-09-12 | ||
| PCT/US2017/050956 WO2018049324A1 (en) | 2016-09-12 | 2017-09-11 | Monocyclic compounds useful as gpr120 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3041033A1 true CA3041033A1 (en) | 2018-03-15 |
Family
ID=61562455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3041033A Pending CA3041033A1 (en) | 2016-09-12 | 2017-09-11 | Monocyclic compounds useful as gpr120 modulators |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10800773B2 (https=) |
| EP (1) | EP3509587B1 (https=) |
| JP (1) | JP7086942B2 (https=) |
| KR (1) | KR102537985B1 (https=) |
| CN (1) | CN110225752B (https=) |
| CA (1) | CA3041033A1 (https=) |
| WO (1) | WO2018049324A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049328A1 (en) * | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
| JP7086942B2 (ja) * | 2016-09-12 | 2022-06-20 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
| IL278077B2 (en) * | 2018-04-20 | 2024-03-01 | Krish Biotech Res Private Limited | Method of treatment of non-alcoholic steatohepatitis, nash |
| US11142525B2 (en) * | 2018-11-15 | 2021-10-12 | Pfizer Inc. | Azalactam compounds as HPK1 inhibitors |
| PE20230323A1 (es) | 2020-05-01 | 2023-02-22 | Pfizer | Compuestos de azalactama como inhibidores de hpk1 |
| IL297600A (en) * | 2020-05-08 | 2022-12-01 | Georgiamune Llc | modulators of akt3 |
| CN114671827B (zh) * | 2020-12-24 | 2024-09-20 | 杭州百新生物医药科技有限公司 | 邻苯甲酰磺酰亚胺类衍生物及其应用 |
| KR102605163B1 (ko) * | 2021-06-01 | 2023-11-23 | 연세대학교 산학협력단 | 뇌암의 예방 또는 치료용 조성물 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2735225A (en) * | 1956-02-21 | Table ix p petri dish tests with x-phthalimido- | ||
| DE2253251A1 (de) | 1972-10-30 | 1974-05-09 | Thomae Gmbh Dr K | Neue phthalimido-sulfonylharnstoffe |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4165435A (en) * | 1976-06-25 | 1979-08-21 | Ciba-Geigy Corporation | Fire retardant s-triazine derivatives |
| EP0145078B1 (en) | 1983-12-02 | 1988-10-12 | Shell Internationale Researchmaatschappij B.V. | Diphenyl ether herbicides |
| FR2659327A1 (fr) | 1990-03-08 | 1991-09-13 | Centre Nat Rech Scient | Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases. |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| DE69224115T2 (de) | 1991-07-30 | 1998-08-20 | Ciba Geigy Ag | Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren |
| US5350761A (en) | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
| TW219935B (https=) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| HUP9902455A3 (en) * | 1996-03-29 | 2000-06-28 | Pfizer | 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them |
| US6716836B2 (en) | 2001-03-22 | 2004-04-06 | Boehringer Ingelheim (Canada) Ltd. | Non-nucleoside reverse transcriptase inhibitors |
| GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| WO2005051373A1 (ja) | 2003-11-26 | 2005-06-09 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| AU2007326395B2 (en) * | 2006-12-01 | 2012-10-11 | Msd K.K. | Novel phenyl-isoxazol-3-ol derivative |
| JP5421783B2 (ja) | 2006-12-27 | 2014-02-19 | サノフイ | Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体 |
| JP5175866B2 (ja) | 2007-02-22 | 2013-04-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇタンパク質共役受容体を調節するための化合物および方法 |
| AU2008218950A1 (en) * | 2007-02-22 | 2008-08-28 | Irm Llc | Thiazole derivatives as modulators of G protein-coupled receptors |
| EP2151236A4 (en) | 2007-04-26 | 2013-01-16 | Japan Science & Tech Agency | G-PROTEIN-CONJUGATED RECEPTOR AGONIST |
| US8569378B2 (en) | 2007-07-20 | 2013-10-29 | Toshiyuki Sakai | p27 protein inducer |
| CA2725316A1 (en) * | 2008-06-02 | 2009-12-10 | Banyu Pharmaceutical Co., Ltd. | Novel isoxazole derivative |
| EA022417B1 (ru) | 2008-10-21 | 2015-12-30 | Саймабэй Терапевтикс, Инк. | Арильные агонисты рецептора gpr120 и их применение |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| EP2406248B1 (en) | 2009-03-11 | 2013-12-25 | Msd K.K. | Novel isoindolin-1-one derivative |
| US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| ES2526124T3 (es) | 2010-06-16 | 2015-01-07 | Cymabay Therapeutics, Inc. | Agonistas del receptor GPR120 y sus usos |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| JP2014520879A (ja) * | 2011-07-15 | 2014-08-25 | ファイザー・インク | Ｇｐｒ１１９調節因子 |
| AR088989A1 (es) * | 2011-11-30 | 2014-07-23 | Hoffmann La Roche | Derivados biciclicos de dihidroisoquinolin-1-ona |
| WO2013139341A1 (en) | 2012-03-20 | 2013-09-26 | Syddansk Universitet | Gpr120 receptor modulators |
| RU2015116540A (ru) * | 2012-10-11 | 2016-12-10 | Мерк Шарп И Доум Корп. | Замещенные соединения спиропиперидинила, применяемые в качестве агонистов gpr120 |
| KR101942752B1 (ko) | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Ｇｐｒ120 효능제로서의 티오아릴 유도체 |
| EP2925746A1 (en) | 2012-12-03 | 2015-10-07 | F. Hoffmann-La Roche AG | Substituted triazole and imidazole compounds |
| EP2935257B1 (en) | 2012-12-20 | 2018-02-07 | Purdue Pharma LP | Cyclic sulfonamides as sodium channel blockers |
| ES2629501T3 (es) | 2013-03-14 | 2017-08-10 | Janssen Pharmaceutica, N.V. | Derivados de pirrol bicíclicos útiles como agonistas de GPR12O |
| US8962660B2 (en) | 2013-03-14 | 2015-02-24 | Bristol-Myers Squibb Company | Oxabicyclo [2.2.2] acid GPR120 modulators |
| KR20150127208A (ko) | 2013-03-14 | 2015-11-16 | 브리스톨-마이어스 스큅 컴퍼니 | 비시클로 [2.2.1] 산 gpr120 조절제 |
| EP2970161B8 (en) | 2013-03-14 | 2018-10-17 | Janssen Pharmaceutica NV | Gpr120 agonists for the treatment of type ii diabetes |
| MX377641B (es) | 2013-03-14 | 2025-03-11 | Janssen Pharmaceutica Nv | Derivados heterocíclicos benzo-fusionados útiles como agonistas del receptor acoplado a proteínas g 120 (gpr120). |
| EP3013796B9 (en) | 2013-06-27 | 2020-07-01 | LG Chem, Ltd. | Biaryl derivatives as gpr120 agonists |
| AR099937A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| EP3140296B1 (en) | 2014-05-07 | 2018-04-11 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |
| SI3186241T1 (sl) | 2014-08-29 | 2021-03-31 | Chdi Foundation, Inc. | Sonde za slikanje Huntingtonovega proteina |
| JP6486699B2 (ja) * | 2015-01-29 | 2019-03-20 | 国立大学法人金沢大学 | 脱水縮合剤 |
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| JP7086942B2 (ja) | 2016-09-12 | 2022-06-20 | インテグラル ヘルス， インコーポレイテッド | Ｇｐｒ１２０モジュレーターとして有用な単環式化合物 |
| WO2018049328A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Bicyclic compounds useful as gpr120 modulators |
-
2017
- 2017-09-11 JP JP2019513935A patent/JP7086942B2/ja active Active
- 2017-09-11 EP EP17849719.4A patent/EP3509587B1/en active Active
- 2017-09-11 CA CA3041033A patent/CA3041033A1/en active Pending
- 2017-09-11 KR KR1020197010269A patent/KR102537985B1/ko active Active
- 2017-09-11 US US16/331,916 patent/US10800773B2/en active Active
- 2017-09-11 WO PCT/US2017/050956 patent/WO2018049324A1/en not_active Ceased
- 2017-09-11 CN CN201780068713.3A patent/CN110225752B/zh active Active
-
2020
- 2020-08-20 US US16/998,660 patent/US11548886B2/en active Active
-
2022
- 2022-10-03 US US17/959,064 patent/US12116362B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3509587A4 (en) | 2020-03-11 |
| WO2018049324A1 (en) | 2018-03-15 |
| EP3509587A1 (en) | 2019-07-17 |
| KR102537985B1 (ko) | 2023-05-30 |
| JP2019530674A (ja) | 2019-10-24 |
| JP7086942B2 (ja) | 2022-06-20 |
| KR20190067174A (ko) | 2019-06-14 |
| US20230183231A1 (en) | 2023-06-15 |
| EP3509587C0 (en) | 2023-12-06 |
| CN110225752A (zh) | 2019-09-10 |
| US20210101896A1 (en) | 2021-04-08 |
| US20190202821A1 (en) | 2019-07-04 |
| US10800773B2 (en) | 2020-10-13 |
| EP3509587B1 (en) | 2023-12-06 |
| CN110225752B (zh) | 2023-05-05 |
| US11548886B2 (en) | 2023-01-10 |
| US12116362B2 (en) | 2024-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12116362B2 (en) | Monocyclic compounds useful as GPR120 modulators | |
| US11919891B2 (en) | Bicyclic compounds useful as GPR120 modulators | |
| EP3606519B1 (en) | Ask1 inhibitor compounds and uses thereof | |
| TWI444378B (zh) | 具有β－分泌酶抑制作用之含硫雜環衍生物及其用途 | |
| US20070149547A1 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| JP2024156867A (ja) | マトリプターゼ２阻害剤及びその使用 | |
| US12077531B2 (en) | Imidazopyridinone compound | |
| TW201619146A (zh) | １－烷基－６－側氧基－１，６－二氫吡啶－３－基化合物及其用途 | |
| US20250179017A1 (en) | Carboxamide compounds as pge2 receptor antagonists | |
| CN120004851A (zh) | Phd抑制剂化合物、组合物和其用途 | |
| CN116438174A (zh) | 化合物及其作为mif抑制剂的用途 | |
| WO2020046975A1 (en) | Methods of treating neurodegenerative diseases | |
| CN116940567A (zh) | 干扰素基因刺激物sting的激动剂 | |
| HK40005332A (en) | Monocyclic compounds useful as gpr120 modulators | |
| HK40005332B (en) | Monocyclic compounds useful as gpr120 modulators | |
| CA3041038C (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005335A (en) | Bicyclic compounds useful as gpr120 modulators | |
| HK40005335B (en) | Bicyclic compounds useful as gpr120 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220812 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20250516 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |